Cannabis company offers personalised treatment plans

An Australian firm is using genetics and AI-based technology to develop personalised medical cannabis treatments for patients. 

Medical cannabis company, Cannaponics, is introducing genetics-based medical cannabis testing for Australian doctors and their patients.

Cannaponics has partnered with GATC Health’s medical cannabis platform to provide medical professionals with the specific data necessary to develop personalised medical cannabis treatment plans, as well as assess their efficacy over time.

GATC Health is a pioneering technology company focused on whole genome testing and Predictive Multiomics™, which will allow doctors to analyse an individual’s genetic response to medical cannabis through its testing platform.

Western Australia-based Cannaponics was awarded a grant from the government’s Collie Futures Industry Development Fund to acquire and develop 160 acres of prime agricultural land in the South West of Western Australia. 

This is Cannaponics’ Cannabis Hemp hub, which will include a world class facility for the cultivation, research and production of cannabis and hemp, including a 72,000sqm greenhouse and a cutting-edge cannabis research and development facility. 

The facility is expected to create up to 1,000 new jobs over the next five years. 

Construction will begin this year with the first harvest to happen in early 2021, followed by a proposed initial public offering (IPO) and listing on the Australian Stock Exchange.

“The medical cannabis industry is an under-served and under-utilized field with significant potential to improve lives,” said John Stroh, interim CEO, GATC Health. 

“We are looking forward to working with Cannaponics to provide patients and physicians with accurate information that could expand the use of medicinal cannabis and improve results of treatment for patients.”

Cannaponics will offer GATC Health’s Medical Cannabis DNA test kit in specialist clinics, as well as via a direct-to-consumer online platform. 

GATC Health’s Medical Cannabis platform can analyse up to 6.4 billion data points, and utilises a unique combination of genetic testing, AI, machine learning and Predictive Multiomics™. 

This analysis is summarised in a personalized, actionable report that addresses the use of medical cannabis for anxiety, pain relief and sleep quality. 

It includes precision dosing guidelines, THC/CBD ratios, CBN and CBG cannabinoid benefits, strain and terpene recommendations, and potential drug interactions.

“Cannaponics is focused on delivering high-quality products and improving access to patients in need,” said D. Stephen Chalk, MA MBBS FRACGP, medical director of Cannaponics. 

“This partnership will allow us to advance the work that we are doing in medical cannabis and provide accurate, personalized recommendations to our customers.” 

Cannaponics is in consultation with the Therapeutics Goods Administration to ensure full compliance with legislation governing In-vitro Diagnostic Testing.